543 related articles for article (PubMed ID: 29930411)
1. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of different screening strategies for cardiovascular diseases prevention in a community-based Chinese population: A decision-analytic Markov model].
Liu QP; Chen XJ; Wang JM; Liu XF; Si YQ; Liang JY; Shen P; Lin HB; Tang X; Gao P
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 53(3):460-466. PubMed ID: 34145845
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness of statin treatment strategies for primary prevention of cardiovascular diseases in a community-based Chinese population: A decision-analytic Markov model].
Gong C; Liu QP; Wang JM; Liu XF; Zhang ML; Yang H; Shen P; Lin HB; Tang X; Gao P
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 54(3):443-449. PubMed ID: 35701120
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of initiation of antihypertensive therapy strategies for primary prevention of cardiovascular diseases in Chinese population: A decision-analytic Markov modelling study].
Zhou T; Liu Q; Zhang M; Liu X; Kang J; Shen P; Lin H; Tang X; Gao P
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):441-447. PubMed ID: 38864129
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of aspirin treatment strategies for primary prevention of cardiovascular diseases: A decision-analytic Markov modelling study].
Zhang ML; Liu QP; Gong C; Wang JM; Zhou TJ; Liu XF; Shen P; Lin HB; Tang X; Gao P
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):480-487. PubMed ID: 37291924
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of different screening strategies for type 2 diabete on preventing cardiovascular diseases in a community-based Chinese population using a decision-analytic Markov model].
Wang JM; Liu QP; Zhang ML; Gong C; Liu SD; Chen WY; Shen P; Lin HB; Gao P; Tang X
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 54(3):450-457. PubMed ID: 35701121
[TBL] [Abstract][Full Text] [Related]
7. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
Blake GJ; Ridker PM; Kuntz KM
Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
10. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
11. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China.
Jiang M; Li P; You JH; Zheng X; Deng J; Zhao M; Feng L; Fang Y
PLoS One; 2019; 14(12):e0224580. PubMed ID: 31790409
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a community-based cardiovascular disease prevention intervention in medically underserved rural areas.
Wang H; Kenkel D; Graham ML; Paul LC; Folta SC; Nelson ME; Strogatz D; Seguin RA
BMC Health Serv Res; 2019 May; 19(1):315. PubMed ID: 31096977
[TBL] [Abstract][Full Text] [Related]
15. [Application of the China-PAR stroke risk equations in a rural northern Chinese population].
Tang X; Zhang DD; Liu XF; Liu QP; Cao Y; Li N; Huang SP; Dou HD; Gao P; Hu YH
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Jun; 52(3):444-450. PubMed ID: 32541976
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
[TBL] [Abstract][Full Text] [Related]
17. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
[TBL] [Abstract][Full Text] [Related]
18. A new selection method to increase the health benefits of CVD prevention strategies.
Lagerweij GR; de Wit GA; Moons KG; van der Schouw YT; Verschuren WM; Dorresteijn JA; Koffijberg H;
Eur J Prev Cardiol; 2018 Apr; 25(6):642-650. PubMed ID: 29411690
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of milk powder fortified with potassium to decrease blood pressure and prevent cardiovascular events among the adult population in China: a Markov model.
Dainelli L; Xu T; Li M; Zimmermann D; Fang H; Wu Y; Detzel P
BMJ Open; 2017 Sep; 7(9):e017136. PubMed ID: 28951410
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
